![]() ![]() Our graduates and faculty produce high-impact biomedical research and advance the practice of medicine. The University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians. This work was supported by seed funding from Minnesota Colorectal Cancer Research Foundation, Mezin-Koats Colon Cancer Research funds and the University of Minnesota Medical School’s Department of Surgery.Ībout the University of Minnesota Medical School The team is currently developing clinical-grade exosomes that can be tested in clinical trials for patients with colorectal cancer. The intellectual property behind the modified exosome technology has been protected with assistance from the U of M Technology Commercialization. Most of the time, the patient’s immune system cannot efficiently fight against tumors, even with the help of the FDA-approved cancer immunotherapies, said Subree Subramanian, PhD, an associate professor in the U of M Medical School’s Department of Surgery and a senior author of the study. “Eliminating the immune suppressive effects of those exosomes is now the focus of a new treatment option for patients with this deadly disease.” ![]() “Our studies indicate that disrupting specific immunosuppressive factors in tumor cells helps unleash the immune system to effectively control tumor growth and metastasis in preclinical models with late-stage colorectal cancer,“ said Subramanian, who is also a member of the Masonic Cancer Center. University of Minnesota Medical School researchers say tumor-secreted exosomes help some cancer cells to evade immune response of current FDA-approved treatment options MINNEAPOLIS/ST.PAUL () In a recent discovery by University of Minnesota Medical School, researchers uncovered a new way to potentially target and treat late-stage colorectal cancer a disease that kills. What they found was recently published in Gastroenterology, including: In partnership with Xianda Zhao, MD, PhD, a postdoctoral fellow in Subramanian’s laboratory, the duo set out to investigate how colorectal cancer becomes resistant to available immunotherapies. Most of the time, the patient’s immune system cannot efficiently fight against tumors, even with the help of the FDA-approved cancer immunotherapies,” said Subree Subramanian, PhD, an associate professor in the U of M Medical School’s Department of Surgery and a senior author of the study. “Late-stage colorectal cancer patients face enormous challenges with current treatment options. The team identified a novel mechanism by which colorectal cancer cells evade an anti-tumor immune response, which helped them develop an exosome-based therapeutic strategy to potentially treat the disease. MINNEAPOLIS/ST.PAUL, Ap(GLOBE NEWSWIRE) - In a recent discovery by University of Minnesota Medical School, researchers uncovered a new way to potentially target and treat late-stage colorectal cancer – a disease that kills more than 50,000 people each year in the United States. Department of Lab Medicine & Pathology University of Minnesota 14-271 Moos Tower (Mail code: MMC 206) 515 Delaware St, S.E Minneapolis, MN-55455 email:subree AT umn DOT edu Tel: 61. ![]() University of Minnesota Medical School researchers say “tumor-secreted exosomes” help some cancer cells to evade immune response of current FDA-approved treatment options ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |